Author Search Results :: UTM Library Massive Scholar Tracking

1

$P109: One-Day Brentuximab-Bendamustine (120mg/m2) every 21 days is a feasible and safe treatment for relapsed/refractory Hodgkin lymphoma$

P109: One-Day Brentuximab-Bendamustine (120mg/m2) every 21 days is a feasible and safe treatment for relapsed/refractory Hodgkin lymphoma by Hannah Moatti, Marie-Céleste Laroque, Loïc. Renaud, Odonchimeg Ravdan, Charlotte Schmidt-Hieber, Isabelle Madelaine, Roberta Di Blasi, Catherine Thieblemont, Pauline Brice

Published 2022-10-01

Get full text

Article

2

Real-world Experience of Approved Chimeric Antigen Receptor T-cell Therapies Compared to Clinical Trials Data by Jérôme Lambert, Roberta Di Blasi, Florence Rabian, Marie-Emilie Dourthe, André Baruchel, Catherine Thiéblemont, Nicolas Boissel, Vincent Levy, Marie-Quitterie Picat, Sylvie Chevret

Published 2023-06-01

Get full text

Article

3

Neurofilament light chain levels as an early predictive biomarker of neurotoxicity after CAR T-cell therapy by Elie Azoulay, Renata Ursu, Antoine F Carpentier, Catherine Thieblemont, Sophie Caillat-Zucman, Marion Larue, Amélie Bouvier, Alexis Maillard, Alexis Cuffel, Vincent Allain, Roberta Di Blasi

Published 2024-09-01

Get full text

Article

4

The use of ICU resources in CAR-T cell recipients: a hospital-wide study by Sandrine Valade, Michael Darmon, Lara Zafrani, Eric Mariotte, Virginie Lemiale, Swann Bredin, Guillaume Dumas, Nicolas Boissel, Florence Rabian, André Baruchel, Isabelle Madelaine, Jérôme Larghero, Anne Brignier, Etienne Lengliné, Stéphanie Harel, Bertrand Arnulf, Roberta Di Blasi, Catherine Thieblemont, Elie Azoulay

Published 2022-08-01

Get full text

Article

5

$Positron emission tomography-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cells$

Positron emission tomography-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cells by Jean Galtier, Laetitia Vercellino, Loic Chartier, Pierre Olivier, Claire Tabouret-Viaud, Charles Mesguich, Roberta Di Blasi, Amandine Durand, Léo Raffy, François-Xavier Gros, Isabelle Madelaine, Veronique Meignin, Miryam Mebarki, Marie-Thérèse Rubio, Pierre Feugier, Olivier Casasnovas, Michel Meignan, Catherine Thieblemont

Published 2022-06-01

Get full text

Article

6

S232: EFFICACY AND TOXICITY OF CAR-T CELLS IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMAS, A NEW REFERENCE: THE FRENCH EXPERIENCE OF THE NATIONAL LOC NETWORK by Sylvain Choquet, Carole Soussain, Magali Legarff-Tavernier, Roberta DI Blasi, Laetitia Souchet, Damien Roos-Weil, Veronique Morel Malek, Madalina Uzunov, Carole Metz, Stéphanie Nguyen-Quoc, Nicolas Gauthier, Lise Willems, Agathe Waultier Rascalou, Celia Salanoubat, Roch Houot, Renata Ursu, Lionel Galicier, Maryline Barrie, Guido Ahle, Blandine Guffroy, Marion Alcantara, Khe Hoang-Xuan, Caroline Houillier

Published 2023-08-01

Get full text

Article

7

$Outcomes of patients with relapsed or refractory primary mediastinal B‐cell lymphoma treated with anti‐CD19 CAR‐T cells: CARTHYM, a study from the French national DESCAR‐T registry$